日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

更正：帕博西尼联合内分泌治疗对一线或二线治疗的 HR+/HER2- 晚期乳腺癌日本患者的总生存期：一项多中心观察性研究（P-BRIDGE 研究）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01787-3
Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Masuda, Hiroko; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Muramatsu, Yasuaki; Kosaka, Nobuyoshi; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Breast reconstruction-related complications from postmastectomy radiation therapy in stage II-III breast cancer: sub-analysis of a multi-institutional observational study (Reborn-03)

II-III期乳腺癌患者乳房切除术后放射治疗引起的乳房重建相关并发症：一项多中心观察性研究的亚组分析（Reborn-03）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01799-z
Sasada, Shinsuke; Tsuji, Wakako; Watanabe, Noriyuki; Shimo, Ayaka; Uehiro, Natsue; Tsukioki, Takahiro; Nagura, Naomi; Tomita, Shoichi; Nogi, Hiroko; Yamaguchi, Kei; Yamagami, Kazuhiko; Ogiya, Akiko; Suetsugu, Hiromi; Nakamura, Yuki; Yamauchi, Chikako; Seki, Hirohito
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group

日本老年HR+/HER2-晚期乳腺癌患者接受帕博西尼联合内分泌治疗的真实世界疗效：P-BRIDGE研究按年龄分组的亚组分析

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01812-5
Masuda, Hiroko; Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Oda, Hirotaka; Muramatsu, Yasuaki; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Development and validation of a nomogram incorporating YpT stage for predicting ypN0 using multicenter data in clinically node-positive breast cancer

利用多中心数据，开发并验证包含 YpT 分期的列线图，用于预测临床淋巴结阳性乳腺癌患者的 ypN0 期

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-32167-8
Shigematsu, Hideo; Sasada, Shinsuke; Hashizume, Junji; Sasada, Tatsunari; Ozaki, Shinji; Noma, Midori; Yoshiyama, Tomoyuki; Noriko, Goda; Kawamata, Ayumi; Emi, Akiko; Kaneko, Yuki; Kajitani, Keiko; Itagaki, Tomoko; Okada, Morihito
肿瘤免疫
肿瘤
乳腺癌
发表日期：2025
文献求助 收藏

Diversity of ER-positive and HER2-negative breast cancer stem cells attained using selective culture techniques

利用选择性培养技术获得的ER阳性和HER2阴性乳腺癌干细胞的多样性

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-90689-7
Sueoka, Satoshi; Kai, Azusa; Kobayashi, Yukino; Ito, Masaoki; Sasada, Shinsuke; Emi, Akiko; Gotoh, Noriko; Arihiro, Koji; Nakayama, Koh; Okada, Morihito; Kadoya, Takayuki
肿瘤
HER2
细胞生物学
肿瘤免疫
乳腺癌
干细胞
发育与干细胞
发表日期：2025
文献求助 收藏

Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy

探讨对于新辅助化疗后达到ypT0的临床淋巴结阳性乳腺癌患者，是否可以省略腋窝手术

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-025-07697-4
Shigematsu, Hideo; Takaya, Momoko; Suzuki, Kanako; Fujimoto, Mutsumi; Ikejiri, Haruka; Amioka, Ai; Hiraoka, Emiko; Sasada, Shinsuke; Arihiro, Koji; Okada, Morihito
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histology

FDG PET/CT在组织学预后不良的特殊类型乳腺癌中的预后价值

期刊:Discover Oncology
影响因子:2.9
doi:10.1007/s12672-025-03278-5
Fujimoto, Mutsumi; Takaya, Momoko; Suzuki, Kanako; Ikejiri, Haruka; Amioka, Ai; Hiraoka, Emiko; Sasada, Shinsuke; Shigematsu, Hideo; Okada, Morihito
肿瘤免疫
肿瘤
乳腺癌
发表日期：2025
文献求助 收藏

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

一线或二线治疗中，帕博西尼联合内分泌治疗对日本 HR+/HER2- 晚期乳腺癌患者的总生存期：一项多中心观察性研究（P-BRIDGE 研究）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01689-4
Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Masuda, Hiroko; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Muramatsu, Yasuaki; Kosaka, Nobuyoshi; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Immediate breast reconstruction surgery for breast cancer: current status and future directions

乳腺癌即刻乳房重建手术：现状与未来方向

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01723-5
Shien, Tadahiko; Nogi, Hiroko; Ogiya, Akiko; Ishitobi, Makoto; Yamauchi, Chikako; Shimo, Ayaka; Narui, Kazutaka; Nagura, Naomi; Seki, Hirohito; Terata, Kaori; Saiga, Miho; Uchida, Tatsuya; Sasada, Shinsuke; Sakurai, Teruhisa; Niikura, Naoki; Mori, Hiroki
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status

2021年国家临床数据库-乳腺癌登记处年度报告：按体重指数和绝经状态分类的特征

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01698-3
Konishi, Takaaki; Kumamaru, Hiraku; Niikura, Naoki; Sagara, Yasuaki; Miyashita, Minoru; Iwamoto, Takayuki; Sanuki, Naoko; Tanakura, Kenta; Nagahashi, Masayuki; Yoshida, Masayuki; Kawashima, Masahiro; Kinoshita, Takayuki; Sasada, Shinsuke; Kinukawa, Naoko; Saji, Shigehira; Ishida, Takanori; Taira, Naruto
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏